{"id":17810,"date":"2021-05-28T09:51:43","date_gmt":"2021-05-28T07:51:43","guid":{"rendered":"https:\/\/idibell.cat\/?p=17810"},"modified":"2021-05-28T09:52:12","modified_gmt":"2021-05-28T07:52:12","slug":"fan-servir-un-model-de-ratoli-per-predir-la-resposta-al-tractament-dun-pacient-amb-mieloma","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/05\/fan-servir-un-model-de-ratoli-per-predir-la-resposta-al-tractament-dun-pacient-amb-mieloma\/","title":{"rendered":"Fan servir un model de ratol\u00ed per predir la resposta al tractament d\u2019un pacient amb mieloma"},"content":{"rendered":"

Un equip de l’IDIBELL i de l’ICO, utilitzant un model ortot\u00f2pic de ratol\u00ed, ha realitzat un estudi d’oncologia personalitzada d’un cas de mieloma molt agressiu. El model mur\u00ed utilitzat, en el qual s’implanta una bi\u00f2psia del tumor hum\u00e0 en el mateix teixit del ratol\u00ed, \u00e9s un dels models in vivo m\u00e9s avan\u00e7ats que existeixen, ja que reprodueix fidelment el comportament del tumor i la seva resposta als tractaments, i que per tant, permet estudiar cada cas individualment.<\/p>\n

En aquest sentit, el present treball publicat a la revista Disease Models and Mechanisms<\/em><\/a>, ha utilitzat el model per estudiar un cas concret de Mieloma Extramedul\u00b7lar M\u00faltiple, determinar-ne les caracter\u00edstiques moleculars i la seva resposta als diferents tractaments. El treball ha estat fruit de la col\u00b7laboraci\u00f3 de dos equips del programa Oncobell de l’IDIBELL i de l’ICO, el grup de recerca en Quimioresist\u00e8ncia Tumoral i Estromal, del programa ProCURE, i el grup de Tumors Hematopo\u00e8tics i Limfoides.<\/p>\n

El Mieloma Multiple ve donat per l’expansi\u00f3 descontrolada de les c\u00e8l\u00b7lules de la medul\u00b7la \u00f2ssia, es tracta d’un tipus de mieloma que gr\u00e0cies als \u00faltims aven\u00e7os ha aconseguit augmentar la taxa de superviv\u00e8ncia. No obstant, hi ha casos en qu\u00e8 les c\u00e8l\u00b7lules malignes aconsegueixen sortir de la medul\u00b7la i colonitzar altres teixits, \u00e9s el cas del Mieloma Multiple Extramedul\u00b7lar<\/strong>, en el qual el pron\u00f2stic empitjora radicalment mostrant una esperan\u00e7a de vida que no supera els tres anys.<\/p>\n

La Dra. Lourdes Farre<\/strong>, l\u00edder del projecte i investigadora principal del grup de recerca en Quimioresist\u00e8ncia Tumoral i Estromal<\/a>, indica “hem demostrat que el model ortot\u00f2pic en ratol\u00ed \u00e9s una eina molt potent per expandir el teixit tumoral procedent de mielomes mantenint les seves caracter\u00edstiques gen\u00e8tiques i histol\u00f2giques, cosa que permet fer un estudi molecular en profunditat i en especial avaluar-ne la resposta tumoral front dels diferents tractaments<\/em>“.<\/p>\n

Per la seva banda, la Dra. Anna Sureda<\/strong> cap del grup Tumors Hematopo\u00e8tics i Limfoides<\/a> ressalta que “determinar el maneig i l’estrat\u00e8gia terap\u00e8utica a seguir en els pacients de Mieloma M\u00faltiple Extramedul\u00b7lar pot ser molt complicat, ja que \u00e9s molt dif\u00edcil predir quin tractament funcionar\u00e0 millor en cada pacient<\/em>“. I afegeix, “gr\u00e0cies a la implantaci\u00f3 del teixit tumoral hum\u00e0 en ratol\u00ed podem estudiar en profunditat les caracter\u00edstiques de cada tumor i combinar-ho amb les diferents opcions terap\u00e8utiques, el que ens podria permetre anar una pas m\u00e9s enll\u00e0 en la medicina personalitzada<\/em>“.<\/p>\n

Aquest treball s\u2019ha finan\u00e7at amb fons competitius del Instituto de Salud Carlos III i de la Fundaci\u00f3n hna.<\/p>\n

 <\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Investigadors de l’IDIBELL i de l’ICO han utilitzat un model ortot\u00f2pic de ratol\u00ed per expandir el teixit tumoral d’un pacient amb aquest tipus de mieloma per estudiar-ne les caracter\u00edstiques moleculars i la resposta a les diferents tractaments<\/p>\n","protected":false},"author":8,"featured_media":17811,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,452,346,449],"tags":[],"class_list":["post-17810","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-procure","category-quimioresistencia-tumoral-i-estromal","category-tumors-hematopoetics-i-limfoides"],"publishpress_future_action":{"enabled":false,"date":"2024-11-29 10:43:54","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/17810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=17810"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/17810\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/17811"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=17810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=17810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=17810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}